Sipuleucel-T (APC8015) for prostate cancer

References

• Jemal A, Murray T, Ward E et al. Cancer Statistics, 2005. CA Cancer J. Clin.55(1), 10–30 (2005).
   PubMed Web of Science ®Google Scholar
• Small EJ, Vogelzang NJ. Second-line hormonal therapy for advanced prostate cancer: a shifting paradigm. J. Clin. Oncol.15(1), 382–388 (1997).
   PubMed Web of Science ®Google Scholar
• Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med.351(15), 1513–1520 (2004).
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med.351(15), 1502–1512 (2004).
   PubMed Web of Science ®Google Scholar
• Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai J. Med.68(3), 160–166 (2001).
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature392(6673), 245–252 (1998).
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Mayordomo JI, Tjandrawan T et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med.183(1), 87–97 (1996).
   PubMed Web of Science ®Google Scholar
• Flamand V, Sornasse T, Thielemans K et al. Murine dendritice cells pulsed in vitro with tumor antigen induced tumor resistance in vivo. Eur. J. Immunol.24(3), 605–610 (1994).
   PubMed Web of Science ®Google Scholar
• Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumor immunity. Nat. Med.1(12), 1297–1302 (1995).
   PubMed Web of Science ®Google Scholar
• Fong L, Engleman EG. Dendritic cells in cancer immunotherapy. Ann. Rev. Immunol.18, 245–273 (2000).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Ciernik IF, Carbone DP. Dendritic cells in antitumor immune response. I. Defective antigen presentation in tumor-bearing hosts. Cell Immunol.170(1), 101–110 (1996).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nadaf S, Corak J et al. Dendritic cells in antimuor immune responses. II. Dendritic cells growth from bone marrow precursors, but not mature DC from tumor-bearing mice, are effective antigen carriers in the therapy of established tumors. Cell Immunol.170(1), 111–119 (1996).
   PubMed Web of Science ®Google Scholar
• Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol.159(10), 4772–4780 (1997).
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Chen HL, Girgis KR et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med.2(10), 1096–1103 (1996).
   PubMed Web of Science ®Google Scholar
• Lee PP, Yee C, Savage PA et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med.5(6), 677–685 (1999).
   PubMed Web of Science ®Google Scholar
• Qin Z, Noffz G, Mohaupt M, Blankenstein T. Interleukin-10 prevents dendritic cell accumulation and vaccination with granulocyte-macrophage colony-stimulating factor gene-modified tumor cells. J. Immunol.159(2), 770–776 (1997).
   PubMed Web of Science ®Google Scholar
• Piali L, Fichtel A, Terpe HJ, Imhof BA, Gisler RH. Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med.181(2), 811–816 (1995).
   PubMed Web of Science ®Google Scholar
• Kuciel R, Mazurkiewicz A, Ostrowski WS et al. Characterization of anti-prostatic acid phosphatase monoclonal antibody and its medical significance. Biotechnol. Appl. Biochem.10(3), 257–272 (1988).
   PubMed Web of Science ®Google Scholar
• Solin T, Kontturi M, Pohlmann R et al. Gene expression and prostate specificity of human prostatic acide phosphatase (PAP): evaluation by RNA blot analyses. Biochim. Biophys. Acta.1048(1), 72–77 (1990).
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. 18(23), 3894–3903 (2000).
   Google Scholar
• Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a Phase I trial of autologous dendritic cells for prostate cancer. Clin. Cancer.6(6), 2175–2182 (2000).
   PubMed Web of Science ®Google Scholar
• Burch PA, Croghan GA, Gastineau DA et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate60(3), 197–204 (2004).
   PubMed Web of Science ®Google Scholar
• Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin. Prostate Cancer4(1), 55–60 (2005).
   PubMedGoogle Scholar
• Rini BI, Weinberg V, Small EJ. A Phase 2 study of prostatic acid phosphatase-pulsed dendritic cells (APC8015; Provenge) in combination with bevacizumab in patients with serologic progression of prostate cancer following local therapy. Multidisciplinary Prostate Cancer SymposiumAbstract 251 (2005).
   Google Scholar
• Schellhammer PF, Hershberg RM. Immunotherapy with autologous antigen presenting cells for the treatment of androgen independent prostate cancer. World J. Urol.23(1), 47–49 (2005).
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano C et al. Results of a placebo-controlled Phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J. Clin. Oncol.24(19), 3089–3094 (2006).
   PubMed Web of Science ®Google Scholar
• Halabi S, Small EJ, Kantoff PW et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J. Clin. Oncol.21(7), 1232–1237 (2003).
   PubMed Web of Science ®Google Scholar
• Smaletz O, Scher HI, Small EJ et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J. Clin. Oncol.20(19), 3972–3982 (2002).
   PubMed Web of Science ®Google Scholar
• Higano C, Burch PA, Small EJ et al. Immunotherapy (APC8015) for androgen independent prostate cancer (AIPC): final progression and survival data from a second Phase III trial. ECCO 13th European Conference, October (2005).
   Google Scholar